GR980100096A - Νεα συνθεση βαλσαλαζιδης - Google Patents

Νεα συνθεση βαλσαλαζιδης

Info

Publication number
GR980100096A
GR980100096A GR980100096A GR980100096A GR980100096A GR 980100096 A GR980100096 A GR 980100096A GR 980100096 A GR980100096 A GR 980100096A GR 980100096 A GR980100096 A GR 980100096A GR 980100096 A GR980100096 A GR 980100096A
Authority
GR
Greece
Prior art keywords
balsalazide
new formulation
formulation
hydroxy
density
Prior art date
Application number
GR980100096A
Other languages
English (en)
Inventor
Harald Heckenmuller
Stefan Friess
Oliver Szambien
Original Assignee
Astra Aktiebolag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20406161&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GR980100096(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Aktiebolag filed Critical Astra Aktiebolag
Publication of GR980100096A publication Critical patent/GR980100096A/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
GR980100096A 1997-03-14 1998-03-06 Νεα συνθεση βαλσαλαζιδης GR980100096A (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9700934A SE9700934D0 (sv) 1997-03-14 1997-03-14 New formulation

Publications (1)

Publication Number Publication Date
GR980100096A true GR980100096A (el) 1998-11-30

Family

ID=20406161

Family Applications (1)

Application Number Title Priority Date Filing Date
GR980100096A GR980100096A (el) 1997-03-14 1998-03-06 Νεα συνθεση βαλσαλαζιδης

Country Status (15)

Country Link
US (1) US6197341B1 (el)
EP (1) EP1003524A1 (el)
JP (1) JP2001519782A (el)
AU (1) AU6430198A (el)
BE (1) BE1011837A5 (el)
BR (1) BR9808140A (el)
CA (1) CA2283297A1 (el)
FR (1) FR2760638A1 (el)
GR (1) GR980100096A (el)
HU (1) HUP0000850A3 (el)
NL (1) NL1008575C2 (el)
NO (1) NO994431L (el)
PL (1) PL335700A1 (el)
SE (1) SE9700934D0 (el)
WO (1) WO1998041212A1 (el)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9700934D0 (sv) * 1997-03-14 1997-03-14 Astra Ab New formulation
DE60115465T2 (de) * 2000-08-29 2006-08-03 Nobex Corp. Immunoregulierende verbindungen, deren derivate und ihre verwendung
CA2421114C (en) * 2000-08-29 2010-12-07 Nobex Corporation 5-asa derivatives having anti-inflammatory and antibiotic activity and methods of treating diseases therewith
US8048924B2 (en) * 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
MY140707A (en) * 2002-02-28 2010-01-15 Mitsubishi Tanabe Pharma Corp Process for preparing a phenylalanine derivative and intermediates thereof
WO2005074908A1 (en) 2004-02-06 2005-08-18 Borody, Thomas, Julius Use of aminosalicylates in diarrhoea-predominent irritable bowel syndrome
US20080306029A1 (en) * 2004-05-28 2008-12-11 Salix Pharmaceuticals, Inc. Prevention, Treatment, and Amelioration of Radiation Induced Enteritis
CN1988897B (zh) * 2004-05-28 2011-06-29 萨利克斯药物有限公司 巴柳氮在制备治疗因放射所引起的肠炎的药物的应用
DK1773767T3 (en) 2004-07-07 2016-03-21 Biocon Ltd Synthesis of azo bound in immune regulatory relations
US7741359B2 (en) * 2005-05-27 2010-06-22 Antibe Therapeutics Inc. Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs
US7498355B2 (en) * 2005-05-27 2009-03-03 Antibe Therapeutics Inc. Derivatives of 4- or 5-aminosalicylic acid
US20060270635A1 (en) * 2005-05-27 2006-11-30 Wallace John L Derivatives of 4- or 5-aminosalicylic acid
WO2006125293A1 (en) * 2005-05-27 2006-11-30 Antibe Therapeutics Inc. Derivatives of 4- or 5-aminosalicylic acid
US8921344B2 (en) * 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US7452872B2 (en) * 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
JP2009506067A (ja) 2005-08-24 2009-02-12 サリックス ファーマシューティカルズ， インコーポレイテッド バルサラジドの製剤ならびにその製造および使用
CN101489986A (zh) * 2006-06-06 2009-07-22 安泰碧治疗公司 曲美布汀和n-去甲基曲美布汀的盐
WO2011137103A1 (en) 2010-04-26 2011-11-03 Salix Pharmaceuticals, Ltd. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives for the treatment of males

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1981002671A1 (en) * 1980-03-20 1981-10-01 Ferring Farma Lab Pharmaceutical composition and method for the treatment of colitis ulcerosa and crohn's disease by oral administration
GB2080796A (en) * 1980-07-21 1982-02-10 Biorex Laboratories Ltd 2-Hydroxy-5-phenylazobenzoic acid derivatives
US5316772A (en) * 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
WO1995018622A1 (en) * 1994-01-07 1995-07-13 Salix Pharmaceuticals, Inc. Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents
WO1998041212A1 (en) * 1997-03-14 1998-09-24 Astra Aktiebolag (Publ) New formulation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4045429A (en) 1970-03-06 1977-08-30 Pharmacia Aktiebolag 4-(4-Hydroxy- or acetoxy-3-carbomethoxyphenylazo)-benzenesulphonyl chloride
BE791889A (fr) 1971-11-26 1973-05-24 Pharmacia Ab Nouveaux derives de la pyridine
US4412992A (en) 1980-07-21 1983-11-01 Biorex Laboratories Limited 2-Hydroxy-5-phenylazobenzoic acid derivatives and method of treating ulcerative colitis therewith
SE9003296L (sv) * 1990-10-16 1992-04-17 Kabi Pharmacia Ab Foerfarande foer att formulera laekemedel

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1981002671A1 (en) * 1980-03-20 1981-10-01 Ferring Farma Lab Pharmaceutical composition and method for the treatment of colitis ulcerosa and crohn's disease by oral administration
GB2080796A (en) * 1980-07-21 1982-02-10 Biorex Laboratories Ltd 2-Hydroxy-5-phenylazobenzoic acid derivatives
US5316772A (en) * 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
WO1995018622A1 (en) * 1994-01-07 1995-07-13 Salix Pharmaceuticals, Inc. Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents
WO1998041212A1 (en) * 1997-03-14 1998-09-24 Astra Aktiebolag (Publ) New formulation

Also Published As

Publication number Publication date
WO1998041212A1 (en) 1998-09-24
AU6430198A (en) 1998-10-12
HUP0000850A2 (hu) 2000-09-28
CA2283297A1 (en) 1998-09-24
NL1008575A1 (nl) 1998-09-15
FR2760638A1 (fr) 1998-09-18
SE9700934D0 (sv) 1997-03-14
JP2001519782A (ja) 2001-10-23
NO994431D0 (no) 1999-09-13
BE1011837A5 (fr) 2000-02-01
EP1003524A1 (en) 2000-05-31
NO994431L (no) 1999-09-13
US6197341B1 (en) 2001-03-06
HUP0000850A3 (en) 2000-10-30
PL335700A1 (en) 2000-05-08
BR9808140A (pt) 2000-03-28
NL1008575C2 (nl) 1999-09-10

Similar Documents

Publication Publication Date Title
GR980100096A (el) Νεα συνθεση βαλσαλαζιδης
GB9806632D0 (en) Peptide factor
EP1045636A4 (en) PHARMACEUTICAL COMPOSITIONS AND METHOD OF USING THE SAME FOR TREATING FAILURE MYOCARDIAL TISSUES
EP0690673A4 (en) SYSTEMIC GENETIC TREATMENT OF TISSUE DISEASES
NO20000688D0 (no) Anvendelse av lokalt avleverte metallioner for behandling av periodontal sykdom
BG104476A (en) Therapeutical form for tolterodin with controlled release
GR970100477A (el) Νεα συνθεση
HK1037861A1 (en) Formulations for the prevention or the treatment of diseases affecting mucosae or skin, or for pregnancy prevention
IL132608A0 (en) Fused dihydropyran compounds medicaments containing the same and the use thereof
DE69429202T2 (de) Therapeutischer Wirkstoff für Erkrankungen des Verdauungstraktes
PT1073416E (pt) Utilização de óxido nítrico inalado como agente anti-inflamatório
IL131407A0 (en) Tetrahydropyrido compounds medicaments containing the same and the use thereof
IL125913A0 (en) Pharmaceutical combination preparation of an inhibitor of the sodium/hydrogen exchanger and medicament for the treatment of cardio-vascular diseases
UA26973A1 (uk) Засіб для профілактики судиhhих захворюваhь, які обумовлеhі дією глікопротеїhзв&#39;язаhих пероксидів
AU7728698A (en) Oral formulations for treatment of bacteria-induced diseases of the colon
PL318130A1 (en) Terpenod derivatives (of sarcodictyine)as antineoplastic agents
KR100488038B1 (ko) 기관 보호 활성을 지닌 신규한 신체 보호 화합물 펩티드염, 이의 제조 방법 및 치료에서의 이의 용도
GB9420747D0 (en) 1,5 benzodiazepine derivatives
TR199700921T1 (xx) �nsanlarda g�r�len herpes-vir�s-8&#39;in tedavisinde pensiklovir&#39;in kullan�lmas�.
HUP9801985A3 (en) Use of cystine derivatives for the preparation of pharmaceutical compositions useful for the treatment of restenosis
HUP9900313A3 (en) Use of anti-oestrogens as male contraceptives
HUP0000570A3 (en) Use of 17 alpha-dihydroequilenin for producing pharmaceutical compositions for the treatment of free radical induced disease states
ZA983211B (en) Use of mizolastine for preparing medication for the treatment of inflammation
IL145297A0 (en) Use of an agent for the manufacture of a medicament for the treatment of bone diseases
HUP0000476A3 (en) Use of 17 betha-dihydroequilenin for producing pharmaceutical compositions for the treatment of free radical induced disease states